For: | Sugimoto R, Furukawa M, Senju T, Aratake Y, Shimokawa M, Tanaka Y, Inada H, Noguchi T, Lee L, Miki M, Maruyama Y, Hashimoto R, Hisano T. Risk factors for de novo hepatitis B during solid cancer treatment. World J Clin Cases 2020; 8(24): 6264-6273 [PMID: 33392307 DOI: 10.12998/wjcc.v8.i24.6264] |
---|---|
URL: | https://www.wjgnet.com/2307-8960/full/v8/i24/6264.htm |
Number | Citing Articles |
1 |
Ryota Horibe, Motohiro Yokota, Koujiro Uemura, Midori Hashimoto, Naoki Kawagishi, Kaoru Nishiyama. <i>De novo</i> Hepatitis B Virus Reactivation During Treatment with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Patient with Advanced Lung Cancer: A Case Report. Internal Medicine 2024; doi: 10.2169/internalmedicine.2731-23
|
2 |
Maki Ohkubo, Emiko Seo, Kosuke Doki, Yoshiharu Suzuki, Ikuo Sekine, Masato Homma. Impact of Hepatitis B Surface and Core Antibody Levels on Hepatitis B Virus Reactivation. Biological and Pharmaceutical Bulletin 2024; 47(5): 941 doi: 10.1248/bpb.b23-00907
|